{"id":30436,"date":"2020-11-11T18:40:29","date_gmt":"2020-11-11T18:40:29","guid":{"rendered":"https:\/\/amelie-project.eu\/?post_type=press-release&p=30436"},"modified":"2021-05-08T07:38:26","modified_gmt":"2021-05-08T07:38:26","slug":"lue-soutient-la-recherche-de-pointe-sur-lincontinence-avec-un-financement-de-95-millions-deuros","status":"publish","type":"press-release","link":"https:\/\/amelie-project.eu\/fr\/communique-de-presse\/lue-soutient-la-recherche-de-pointe-sur-lincontinence-avec-un-financement-de-95-millions-deuros\/","title":{"rendered":"L'UE soutient la recherche de pointe sur l'incontinence gr\u00e2ce \u00e0 un financement de 9,5 millions d'euros"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.6.3″ custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.6.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” module_alignment=”center” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.3″ text_font=”Gotham kinda bold||||||||” text_text_color=”#000000″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”]<\/p>\n

L'Union europ\u00e9enne a accord\u00e9 9,5 millions d'euros \u00e0 un projet de recherche novateur sur le traitement de l'incontinence f\u00e9cale.<\/p>\n

L'objectif de la recherche est d'utiliser une th\u00e9rapie cellulaire r\u00e9volutionnaire pour trouver un rem\u00e8de possible \u00e0 une maladie qui touche environ 67 millions de personnes en Europe.<\/p>\n

Le financement ira \u00e0 un consortium de 13 organisations r\u00e9parties dans neuf pays, appel\u00e9 AMELIE (Anchored Muscle cELls for Incontinence).<\/p>\n

Le projet sera coordonn\u00e9 par l'UCL et dirig\u00e9 par Richard Day, professeur de technologie de m\u00e9decine r\u00e9g\u00e9n\u00e9rative \u00e0 l'UCL.<\/p>\n

Les autres partenaires au Royaume-Uni sont l'universit\u00e9 Queen Mary de Londres, le NHS Blood and Transplant et l'organisation caritative Bowel Research UK, qui jouera un r\u00f4le de premier plan dans la participation des patients.<\/p>\n

La recherche sera men\u00e9e sur cinq ans, des institutions distinctes au Royaume-Uni, en Espagne et au Portugal jouant le r\u00f4le de chef de file \u00e0 chaque nouvelle \u00e9tape.<\/p>\n

Le projet consistera \u00e0 pr\u00e9lever les cellules musculaires du patient, \u00e0 les charger sur des microporteurs sp\u00e9cialement con\u00e7us et \u00e0 les implanter dans le muscle endommag\u00e9 afin de favoriser la r\u00e9g\u00e9n\u00e9ration et de r\u00e9tablir une fonction normale.<\/p>\n

Le professeur Day a d\u00e9clar\u00e9 qu'une telle th\u00e9rapie de m\u00e9decine r\u00e9g\u00e9n\u00e9rative offre un espoir \u00e0 de nombreuses personnes dont la vie est gravement perturb\u00e9e par l'incontinence :<\/p>\n

\u201cNous sommes extr\u00eamement enthousiastes \u00e0 l'id\u00e9e du projet AMELIE et des avantages potentiels qui peuvent d\u00e9couler de la nouvelle approche th\u00e9rapeutique \u00e0 l'\u00e9tude.<\/p>\n

\u201cNous sommes impatients de travailler avec le consortium exceptionnel d'universitaires, de cliniciens, d'industriels et d'associations caritatives de toute l'Europe pour d\u00e9velopper notre approche pionni\u00e8re de la m\u00e9decine r\u00e9g\u00e9n\u00e9rative dans le traitement de cette maladie d\u00e9bilitante.<\/p>\n

\u201cIl s'agit d'une approche radicale et innovante qui n'a jamais \u00e9t\u00e9 tent\u00e9e \u00e0 une telle \u00e9chelle.\u201d<\/p>\n

Lesley Booth MBE, directrice de la recherche et des IPP \u00e0 Bowel Research UK, a d\u00e9clar\u00e9 que, bien que la maladie soit extr\u00eamement courante, on n'en parle pas beaucoup.<\/p>\n

\u201cLa r\u00e9alit\u00e9 de l'incontinence f\u00e9cale peut \u00eatre d\u00e9vastatrice. Elle limite d\u00e9finitivement l'esp\u00e9rance de vie. Et le fait que les gens n'en parlent pas librement ne fait qu'ajouter aux difficult\u00e9s de mener une vie normale\u201d, a-t-elle d\u00e9clar\u00e9.<\/p>\n

\u201cTrouver une th\u00e9rapie efficace ne serait pas seulement une avanc\u00e9e m\u00e9dicale majeure, cela changerait la vie de millions de personnes\u201d.\u201d<\/p>\n

Ce projet a re\u00e7u un financement du programme de recherche et d'innovation Horizon 2020 de l'Union europ\u00e9enne dans le cadre de la convention de subvention n\u00b0 874807.<\/p>\n

\n

<\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/amelie-project.eu\/wp-content\/uploads\/2021\/01\/Picture-1.png” title_text=”Picture 1″ _builder_version=”4.6.3″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence. The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE). The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL. Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement. The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage. The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function. Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence: \u201cWe are tremendously excited by the prospect of the AMELIE project […]<\/p>","protected":false},"featured_media":31025,"template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\n

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence.<\/p>\n\n\n\n

The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. <\/p>\n\n\n\n

The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n\n\n\n

The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL.<\/p>\n\n\n\n

Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement.<\/em><\/p>\n\n\n\n

The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage.<\/p>\n\n\n\n

The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function.<\/p>\n\n\n\n

Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence:<\/p>\n\n\n\n

\u201cWe are tremendously excited by the prospect of the AMELIE project and the potential benefits that may arise from the new therapeutic approach being investigated.<\/p>\n\n\n\n

\u201cWe look forward to working with the exceptional consortium of academics, clinicians, industry and charity partners from across Europe to develop our pioneering regenerative medicine approach for treating this debilitating condition.<\/p>\n\n\n\n

\u201cThis will be a radical and innovative approach never before attempted at such a scale.\u201d<\/p>\n\n\n\n

Lesley Booth MBE, Director of Research and PPI at Bowel Research UK, said that, whilst the condition is extremely common, it is not much talked about.<\/p>\n\n\n\n

\u201cThe reality of living with faecal incontinence can be devastating. It is definitely life-limiting. And the fact that it\u2019s a condition which people don\u2019t discuss freely just adds to the difficulties of leading a normal life,\u201d she said.<\/p>\n\n\n\n

\u201cFinding a therapy which works would not just be a major medical breakthrough, it would be life-changing for millions.\u201d<\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

Ends<\/strong><\/p>\n\n\n\n

NOTES TO EDITORS<\/strong><\/p>\n\n\n\n

AMELIE<\/strong> (Anchored Muscle cELls for IncontinencE consortium) is made up of the following: University College London, Instituto Superior Tecnico (Portugal), Queen Mary University of London, Medical University of Graz (Austria), Aarhus University Hospital (Denmark), Rouen University Hospital (France), University Hospital Erlangen (Germany), Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (Spain), NHS Blood and Transplant (UK), Polysciences Europe GmbH (Germany), Ttopstart (Netherlands), Bowel Research (UK), Consorzio per Valutazioni Biologiche e Farmacologiche (Italy).<\/p>\n\n\n\n

Horizon 2020<\/strong> is an EU funding programme for research and innovation. It is the biggest EU Research and Innovation programme ever with nearly \u20ac80 billion of funding available over 7 years (2014 to 2020) \u2013 in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. https:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/what-horizon-2020<\/a><\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

AMELIE contact:<\/strong><\/p>\n\n\n\n

Media contact:<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_links_to":"","_links_to_target":""},"categories":[51],"class_list":["post-30436","press-release","type-press-release","status-publish","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/amelie-project.eu\/fr\/wp-json\/wp\/v2\/press-release\/30436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amelie-project.eu\/fr\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/amelie-project.eu\/fr\/wp-json\/wp\/v2\/types\/press-release"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amelie-project.eu\/fr\/wp-json\/wp\/v2\/media\/31025"}],"wp:attachment":[{"href":"https:\/\/amelie-project.eu\/fr\/wp-json\/wp\/v2\/media?parent=30436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amelie-project.eu\/fr\/wp-json\/wp\/v2\/categories?post=30436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}